NewsRoom Articles - Page 68 of 154 - PsychedelicNewsWire (PNW)

ThursdayFeb 24, 2022 3:50 pm

VIU Set to Launch First Psychedelics Therapy Course in Canada

Vancouver Island University (“VIU”) plans to launch its psychedelic-assisted therapy course in September of this year. This will make it the first accredited university in Canada to offer this course for healthcare professionals, under its Faculty of Health and Human Services. Shannon Dames, the institution’s nursing professor, stated that this launch was significant because it recognized that psychedelic-assisted therapy was an advanced practice that required a unique skill set. Laura McLean, one of the program’s registrants, signed up after she tried therapy under Roots to Thrive. Roots to Thrive is a 12-week program with virtual sessions that feature guided discussions…

WednesdayFeb 23, 2022 2:31 pm

A Review of Recent Moves Made by Psychedelic Companies

A lot has happened over the past weeks in the psychedelics industry. Below, we look at some of the moves companies in this burgeoning sector have made. Last week, Core One Labs Inc. researchers at its Vocan Biotechnologies Inc. subsidiary had received positive results and would begin using its recombinant production system to produce API-Grade N-methyltryptamine, or NMT. NMT is also known as MMT, or monomethyl tryptamine, and is a DMT precursor that the company will be producing to expand its psychedelic product pipeline. The firm is currently using its proprietary recombinant production system to produce psilocybin. In a recent…

WednesdayFeb 23, 2022 10:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics

Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSD These results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizon Mydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds by undertaking clinical research in partnership with academics In a recent interview, company CEO Josh Bartch emphasized the need for consistent messaging to push the adoption of psychedelics among the medical community, and help assuage concerns of patients who may be wary of psychedelic treatments…

TuesdayFeb 22, 2022 2:28 pm

Insights into Life and Psychedelics from Psychedelics Pioneers

Psychedelics pioneers have for many years argued that the substances enhance perception in a way that is healing and extraordinary. Below are powerful insights into human nature from a couple of psychonaut academics, writers and philosophers. Anaïs Nin Anaïs Nin was a French-Cuban-American writer who was consulted by doctors to improve their understanding of LSD’s effects. Nin participated in an LSD experiment in the fall of 1955, which was carried out by Oscar Janiger, an experimental psychiatrist best known for his research on LSD. Nin described the experience as the most pleasurable sensation she’d ever known, noting that it was…

TuesdayFeb 22, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Seeks to Capitalize on the Growing Market for Psychedelics in Healthcare

The global psychedelics market is estimated to hit $10.75 billion in 2027, with the alternative antidepressant drug market being valued at $15.98 billion in 2023 Already, 65% of individuals dealing with PTSD, depression, and anxiety in the United States believe that psychedelic medicine should be made available 83% of Americans living with these conditions are open to trying out alternative treatments Delic seeks to capitalize on this growing demand for psychedelic alternatives, coupled with ongoing legislative and regulatory changes to grow its brand and increase value for its shareholders While the psychedelics industry might be in its early stages, its…

FridayFeb 18, 2022 1:04 pm

Study Finds That Psychedelics Can Alter Core Metaphysical Beliefs

A new study has found that psychedelic substances can alter an individual’s core beliefs about the nature of free will, consciousness and reality. The study’s findings were reported in the “Scientific Reports” journal. The researchers’ objective was to find out whether psychedelics had the capacity to change a person’s core metaphysical beliefs, because the drugs can induce spiritual encounters and transformative experiences. Metaphysical beliefs are ideas about reality’s fundamental nature. The study was carried out by a team of researchers led by Christopher Timmermann, who examined the metaphysical beliefs of participants before and after they had used psychedelics. The researchers…

ThursdayFeb 17, 2022 10:15 am

Maryland Senators File Measure to Offer Veterans Free Access to Psychedelics

Earlier this week, a group of senators in the state of Maryland filed a measure which would establish a fund that could be used to support research into the therapeutic potential of psychedelics. The bill also called for providing free access to psychedelic drugs such as ketamine, MDMA and psilocybin for military veterans with PTSD. The bill, which was sponsored by Sen. Sarah Elfreth, would create a PTSD Alternative Therapies fund. The state fund would finance studies on psychedelics through Maryland’s Department of Health as well as offer cost-free access to alternative therapies. The measure stipulates that regulators will have…

WednesdayFeb 16, 2022 3:08 pm

Advocates Challenge DEA’s Proposal to Schedule Five Psychedelic Compounds

Researchers and advocates are challenging the DEA’s proposal to classify a series of psychedelic compounds under Schedule I of the Controlled Substances Act. The Drug Enforcement Administration published a scheduling proposal in the Federal Register in January that highlights its plan to ban the following tryptamines: DiPT, 5-MeO-DET, 5-MeO-MiPT, 5-MeO-AMT and 4-OH-DiPT. The DEA wants to classify these tryptamines under the same category as drugs such as LSD, cannabis and heroin. The agency stated that before it made the proposal, it conducted its own analyses as well as considered research and recommendations from the Department of Health and Human Services,…

TuesdayFeb 15, 2022 3:08 pm

Utah House Committee Approves Measure Allowing Research on Mental Health Benefits of Psychedelics

Last week, a House committee in the state of Utah passed a measure that would establish a task force to conduct research on and give recommendations for the therapeutic potential of psychedelic substances and regulations governing their legal use. The bill, which was sponsored by Rep. Brady Brammer, was approved by the House Health and Human Services Committee in a 10-to-1 vote. The bill stipulates that the task force would be required to research and give recommendations on drugs that could assist in mental illness treatment. The drugs to be considered included controlled substances that had the potential to manage,…

TuesdayFeb 15, 2022 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment options The license allows Mydecine to provide psilocybin and MDMA (Ecstasy) through its licensed Alberta facility and collaboration with non-profit drug development institute Applied Pharmaceutical Innovation The company has named pharmaceutical scientist and entrepreneur Dr. Victoria Hale to its Board of Directors, strengthening…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000